Improving on BCG.
BCG is the only vaccine for tuberculosis and leprosy known to be effective in at least some places. Unfortunately it tends to be less successful in just those areas of the developing world where a vaccine is most needed. Although molecular biology offers the prospect of alternatives, these still lie in the indefinite future, and the best use has to be made of BCG. A number of preparations are available from different manufacturers, and a vaccine should be selected with good evidence of efficacy, and a low incidence of complications. Selection of the optimal age for administering BCG should be based on factors pertaining in the area where it is to be used. The influence of contact with environmental mycobacteria, the age at which mycobacterial diseases occur, and the logistics of vaccine delivery must be taken into account. The addition of a suspension of killed Mycobacterium vaccae to BCG may increase its efficacy. Skin test data show that recognition of antigens common to all mycobacterial species and thought to be the first step in the protective immune response, is significantly enhanced by the additive. M. vaccae also contains a substance, or substances, "switching off" the tissue destructive aspect of the Koch phenomenon that is part of the immunopathology of tuberculosis. A suspension of killed M. vaccae alone can be used to enhance immune responses of persons unsuitable for BCG vaccination, such as those already tuberculin positive, and those with scars of earlier BCG vaccination.
Stanford
J L
JL
Department of Microbiology, School of Pathology, University College and Middlesex School of Medicine, London, U.K.
D000367:Age Factors; D000818:Animals; D001500:BCG Vaccine / Q000276:immunology / Q000592:standards*; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D014374:Tuberculin Test; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000276:immunology
D001500:BCG Vaccine; D015164:Vaccines, Inactivated